Published : Aug-2021
No. of Pages : 55
1 Executive Summary
1.1 Executive Summary
2 Disease Overview
2.1 Overview of Cushing's Syndrome
2.2 Cushing's Syndrome SWOT Analysis
2.3 Classification of Cushing's Syndrome
3 Epidemiology
3.1 Diagnosed Prevalent Cases of CS, 2020-2030
3.2 Diagnosed Prevalent Cases of CS by Specific Type, 2020
3.3 Sources and Methodology
3.4 Diagnosis of Cushing's Syndrome - Treatable Population
4 Current Treatment Options
4.1 Treatment Paradigm
4.2 Marketed Products
4.3 Product Profile: Corcept Therapeutics' Korlym (mifepristone)
4.4 Product Profile: Recordati SpA's Isturisa (osilodrostat phosphate)
4.5 Product Profile: Recordatii SpAs Signifor (pasireotide)
4.6 Product Profile: Laboratorie HRA Pharma SAS' Ketoconazole
4.7 Product Profile: Laboratorie HRA Pharma SAS' Metopirone (metyrapone)
4.8 Product Profile: Laboratorie HRA Pharma SAS' Lysodren (mitotane)
5 Unmet Needs and Opportunities
5.1 Unmet Needs in CS
5.2 Efficacious Therapies that Target Underlying Causes of CD
5.3 Therapies for Severe CS with Improved Efficacy and Safety
5.4 Physician Awareness of CS Symptomatology
5.5 Improved Referral Systems to Specialists in Secondary Healthcare Settings
5.6 Defined Guidelines for Treatment and Remission
6 Pipeline Assessment
6.1 Cushing's Syndrome Pipeline Overview
6.2 Leading Pipeline Agents
6.3 Product Profile: Recorlev
6.4 Product Profile: Relacorilant
6.5 Product Profile: SPI-62
6.6 Pipeline Products - Review Designations
6.7 Cushing's Syndrome: Clinical Trials Overview, Phase II/III
7 R&D Strategies
7.1 Trends in Clinical Trial Design in Cushing's Syndrome
7.2 Trends in Deal-Making in Cushing's Syndrome
8 Market Outlook
8.1 Cushing's Syndrome Sales Forecast
8.2 Cushing's Syndrome Market Forecast
8.3 Market Drivers and Barriers
9 Appendix
9.1 Primary Research: KOL Information
9.2 About the Authors
10 Contact Us
List of Figures
Figure 1: Summary of Key Findings
